Details of the Drug

General Information of Drug (ID: DMW649X)

Drug Name
Eletriptan
Synonyms
Eletriptanum; Relpax; UK 116044; UK116044; Eletriptan (INN); Eletriptan [INN:BAN]; Relpax (TN); UK-116044; UK-116044-04; (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-Indole; (R)-5-[2-(Benzenesulfonyl)ethyl]-3-[(N-methylpyrrolidin-2-yl)methyl]-1H-indole; 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole; 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole; 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1], [2]
Therapeutic Class
Antimigraine Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 382.5
Topological Polar Surface Area (xlogp) 4.1
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 50% [4]
Clearance
The renal clearance of drug is 3.9 L/h [5]
Elimination
5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 hours [6]
Metabolism
The drug is metabolized via the cytochrome P-450 enzyme CYP3A4 [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.494 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.15% [6]
Vd
The volume of distribution (Vd) of drug is 138 L [5]
Water Solubility
The ability of drug to dissolve in water is measured as 4 mg/mL [3]
Chemical Identifiers
Formula
C22H26N2O2S
IUPAC Name
5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
Canonical SMILES
CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
InChI
InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
InChIKey
PWVXXGRKLHYWKM-LJQANCHMSA-N
Cross-matching ID
PubChem CID
77993
ChEBI ID
CHEBI:50922
CAS Number
143322-58-1
DrugBank ID
DB00216
TTD ID
D02DMQ
VARIDT ID
DR00981
INTEDE ID
DR0564
ACDINA ID
D00223

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1B receptor (HTR1B) TTK8CXU 5HT1B_HUMAN Modulator [8]
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Eletriptan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Eletriptan and Methylene blue. Acquired methaemoglobinaemia [3A93] [59]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Eletriptan and Oliceridine. Acute pain [MG31] [60]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Eletriptan caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [61]
Nifedipine DMSVOZT Moderate Decreased metabolism of Eletriptan caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [61]
Posaconazole DMUL5EW Major Decreased metabolism of Eletriptan caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [61]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Eletriptan caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [61]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Eletriptan and Desipramine. Attention deficit hyperactivity disorder [6A05] [62]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Eletriptan and Droxidopa. Autonomic nervous system disorder [8D87] [63]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Eletriptan caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Eletriptan caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Clarithromycin DM4M1SG Major Decreased metabolism of Eletriptan caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Eletriptan caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Eletriptan and Linezolid. Bacterial infection [1A00-1C4Z] [64]
Troleandomycin DMUZNIG Major Decreased metabolism of Eletriptan caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Telithromycin DMZ4P3A Major Decreased metabolism of Eletriptan caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Eletriptan caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Tucatinib DMBESUA Major Decreased metabolism of Eletriptan caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Eletriptan caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [61]
Morphine DMRMS0L Moderate Additive CNS depression effects by the combination of Eletriptan and Morphine. Chronic pain [MG30] [60]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Eletriptan and Levomilnacipran. Chronic pain [MG30] [62]
Methadone DMTW6IU Moderate Additive serotonergic effects by the combination of Eletriptan and Methadone. Cough [MD12] [60]
Mifepristone DMGZQEF Major Decreased metabolism of Eletriptan caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [65]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Eletriptan caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [61]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Eletriptan caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [61]
MK-8228 DMOB58Q Moderate Decreased metabolism of Eletriptan caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [61]
Aprepitant DM053KT Moderate Decreased metabolism of Eletriptan caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [61]
Sertraline DM0FB1J Major Additive serotonergic effects by the combination of Eletriptan and Sertraline. Depression [6A70-6A7Z] [62]
Fluoxetine DM3PD2C Major Additive serotonergic effects by the combination of Eletriptan and Fluoxetine. Depression [6A70-6A7Z] [62]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Eletriptan and Vilazodone. Depression [6A70-6A7Z] [62]
Nefazodone DM4ZS8M Major Decreased metabolism of Eletriptan caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [61]
Paroxetine DM5PVQE Major Additive serotonergic effects by the combination of Eletriptan and Paroxetine. Depression [6A70-6A7Z] [62]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Eletriptan and Vortioxetine. Depression [6A70-6A7Z] [62]
Duloxetine DM9BI7M Major Additive serotonergic effects by the combination of Eletriptan and Duloxetine. Depression [6A70-6A7Z] [62]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Eletriptan and Isocarboxazid. Depression [6A70-6A7Z] [59]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Eletriptan and Milnacipran. Depression [6A70-6A7Z] [62]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Eletriptan and Escitalopram. Depression [6A70-6A7Z] [62]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Eletriptan and Tranylcypromine. Depression [6A70-6A7Z] [59]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Eletriptan and Desvenlafaxine. Depression [6A70-6A7Z] [62]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Eletriptan and Phenelzine. Depression [6A70-6A7Z] [59]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Eletriptan and Trazodone. Depression [6A70-6A7Z] [62]
Venlafaxine DMR6QH0 Major Additive serotonergic effects by the combination of Eletriptan and Venlafaxine. Depression [6A70-6A7Z] [62]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Eletriptan and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [66]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Eletriptan and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [62]
Stiripentol DMMSDOY Moderate Decreased metabolism of Eletriptan caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Rufinamide DMWE60C Moderate Increased metabolism of Eletriptan caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Itraconazole DMCR1MV Major Decreased metabolism of Eletriptan caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [61]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Eletriptan caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [61]
Ketoconazole DMPZI3Q Major Decreased metabolism of Eletriptan caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [61]
Cimetidine DMH61ZB Moderate Decreased metabolism of Eletriptan caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [61]
Boceprevir DMBSHMF Major Decreased metabolism of Eletriptan caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [61]
Telaprevir DMMRV29 Major Decreased metabolism of Eletriptan caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [61]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Eletriptan caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [61]
Rifapentine DMCHV4I Moderate Increased metabolism of Eletriptan caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [68]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Eletriptan and Procarbazine. Hodgkin lymphoma [2B30] [59]
Indinavir DM0T3YH Major Decreased metabolism of Eletriptan caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Delavirdine DM3NF5G Major Decreased metabolism of Eletriptan caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Eletriptan caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Nevirapine DM6HX9B Moderate Increased metabolism of Eletriptan caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Cobicistat DM6L4H2 Major Decreased metabolism of Eletriptan caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Efavirenz DMC0GSJ Moderate Increased metabolism of Eletriptan caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Saquinavir DMG814N Major Decreased metabolism of Eletriptan caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Amprenavir DMLMXE0 Major Decreased metabolism of Eletriptan caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Darunavir DMN3GCH Moderate Decreased metabolism of Eletriptan caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Atazanavir DMSYRBX Major Decreased metabolism of Eletriptan caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Ritonavir DMU764S Major Decreased metabolism of Eletriptan caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Eletriptan caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [61]
Verapamil DMA7PEW Moderate Decreased metabolism of Eletriptan caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [61]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Eletriptan caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [61]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Eletriptan caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [61]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Eletriptan caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [61]
Crizotinib DM4F29C Moderate Decreased metabolism of Eletriptan caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [61]
Ceritinib DMB920Z Major Decreased metabolism of Eletriptan caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [61]
PF-06463922 DMKM7EW Moderate Increased metabolism of Eletriptan caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [71]
Selpercatinib DMZR15V Moderate Decreased metabolism of Eletriptan caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [61]
Idelalisib DM602WT Major Decreased metabolism of Eletriptan caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [61]
IPI-145 DMWA24P Moderate Decreased metabolism of Eletriptan caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [61]
Danazol DML8KTN Moderate Decreased metabolism of Eletriptan caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [61]
Exjade DMHPRWG Moderate Decreased metabolism of Eletriptan caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [72]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Eletriptan and Ozanimod. Multiple sclerosis [8A40] [73]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Eletriptan caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [61]
Nilotinib DM7HXWT Moderate Decreased metabolism of Eletriptan caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [61]
Imatinib DM7RJXL Moderate Decreased metabolism of Eletriptan caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [61]
Dasatinib DMJV2EK Moderate Decreased metabolism of Eletriptan caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [61]
Modafinil DMYILBE Minor Increased metabolism of Eletriptan caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [74]
Palonosetron DMBHMOX Major Additive serotonergic effects by the combination of Eletriptan and Palonosetron. Nausea/vomiting [MD90] [75]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Eletriptan and Granisetron. Nausea/vomiting [MD90] [75]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Eletriptan and Dolasetron. Nausea/vomiting [MD90] [75]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Eletriptan and Ondansetron. Nausea/vomiting [MD90] [75]
Entrectinib DMMPTLH Moderate Decreased metabolism of Eletriptan caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [61]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Eletriptan and Sibutramine. Obesity [5B80-5B81] [59]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Eletriptan and Lorcaserin. Obesity [5B80-5B81] [76]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Eletriptan and Dexfenfluramine. Obesity [5B80-5B81] [62]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Eletriptan and Levomethadyl Acetate. Opioid use disorder [6C43] [60]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Eletriptan caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [61]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Eletriptan and Oxymorphone. Pain [MG30-MG3Z] [60]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Eletriptan and Levorphanol. Pain [MG30-MG3Z] [60]
Hydromorphone DMHP21E Moderate Additive CNS depression effects by the combination of Eletriptan and Hydromorphone. Pain [MG30-MG3Z] [60]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Eletriptan and Dezocine. Pain [MG30-MG3Z] [60]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Eletriptan and Nalbuphine. Pain [MG30-MG3Z] [60]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Eletriptan and Buprenorphine. Pain [MG30-MG3Z] [60]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Eletriptan and Hydrocodone. Pain [MG30-MG3Z] [60]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Eletriptan and Oxycodone. Pain [MG30-MG3Z] [60]
Abametapir DM2RX0I Moderate Decreased metabolism of Eletriptan caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [77]
Lefamulin DME6G97 Moderate Decreased metabolism of Eletriptan caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [78]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Eletriptan caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [61]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Eletriptan caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [61]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Eletriptan and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [79]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Eletriptan and Fentanyl. Sensation disturbance [MB40] [62]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Eletriptan caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [61]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Eletriptan caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [67]
Larotrectinib DM26CQR Moderate Decreased metabolism of Eletriptan caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [61]
Armodafinil DMGB035 Minor Increased metabolism of Eletriptan caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [74]
LEE011 DMMX75K Moderate Decreased metabolism of Eletriptan caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [61]
Pitolisant DM8RFNJ Moderate Increased metabolism of Eletriptan caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [67]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Eletriptan caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [80]
Brilinta DMBR01X Moderate Decreased metabolism of Eletriptan caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [61]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Eletriptan and Tizanidine. Tonus and reflex abnormality [MB47] [81]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Eletriptan and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [79]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Eletriptan and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [79]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Eletriptan caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [61]
⏷ Show the Full List of 120 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Eletriptan 20 mg tablet 20 mg Oral Tablet Oral
Eletriptan 40 mg tablet 40 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 40).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
12 Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
30 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
31 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
32 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
33 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
34 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
35 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
36 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
37 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
38 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
39 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
40 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
41 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
42 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
43 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
44 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
45 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
46 Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
47 Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
48 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
49 Company report (NeurAxon)
50 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
51 Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.
52 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
53 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
54 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
55 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
56 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
57 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
58 Company report (Fabrekramer)
59 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
60 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
61 Product Information. Relpax (eletriptan). Pfizer U.S. Pharmaceuticals, New York, NY.
62 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
63 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
64 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
65 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
66 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
67 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
68 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
69 Cerner Multum, Inc. "Australian Product Information.".
70 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
71 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
72 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
73 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
74 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
75 Canadian Pharmacists Association.
76 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
77 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
78 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
79 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
80 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
81 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.